Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. is positioned favorably due to its innovative development of cannabinoid-based formulations targeting impactful conditions, including Alzheimer's disease and chronic pain. The company’s investigational drug assets, particularly IGC-AD1, have demonstrated promising preclinical results by potentially addressing critical Alzheimer’s disease hallmarks, which may drive future advancements and market interest. Additionally, the maintenance of an attractive current valuation and the expectation of positive data as catalysts further support a positive outlook for the company's stock.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(0.02), which aligns with prior estimates but reflects ongoing financial challenges. The company's investigational products targeting Alzheimer's disease face significant risks, including failure to demonstrate safety and efficacy, regulatory approval hurdles, and commercialization difficulties, all of which could impede future revenue generation. Additionally, liquidity risks and macroeconomic factors further exacerbate the uncertain outlook for the company's financial health and stock performance.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.